Functional assays with the TLR4 inhibitor TAK-242 demonstrated that TLR4 blockade reversed rhENO1-induced tumor proliferation, migration, and invasion (Fig. 4I–L), confirming TLR4’s role in ENO1-driven malignancy. Here, TLR4 is linked to neoplasm.